CRVS · Corvus Pharmaceuticals, Inc.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $45.53M | $33.72M | $19.39M | $16.53M | $24.47M | $29.12M | $31.83M | $37.98M | $38.59M | $46.31M | $29.36M | $11.35M | — | |
| $11.43M | $9.25M | $8.16M | $6.88M | $8.1M | $9.52M | $11.93M | $10.88M | $10.64M | $10.22M | $7.62M | $2.42M | — | |
| $117K | $105K | $85K | $151K | $367K | $460K | $632K | $743K | $847K | $842K | $594K | $148K | — | |
| $56.96M | $42.97M | $27.55M | $23.41M | $32.57M | $38.63M | $43.76M | $48.85M | $49.22M | $56.52M | $36.98M | $13.77M | — | |
| — | — | — | — | — | — | — | — | — | — | $36.98M | $13.77M | — | |
| -$56.96M | -$42.97M | -$27.55M | -$23.41M | -$32.57M | -$38.63M | -$43.76M | -$48.85M | -$49.22M | -$56.52M | -$36.98M | -$13.77M | — | |
| -$2.34M | -$1.96M | -$3.2M | -$5.28M | -$10.01M | — | — | — | — | — | — | — | — | |
| -$51.79M | -$13.33M | -$59.1M | -$21.75M | -$41.31M | -$43.24M | -$6M | -$46.67M | -$46.94M | -$55.66M | -$36.38M | -$31.34M | -$161K | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$54.13M | -$15.28M | -$62.29M | -$27.03M | -$41.31M | -$43.24M | -$6M | -$46.67M | -$46.94M | -$55.66M | -$36.38M | -$31.34M | — | |
| -$54.13M | -$15.28M | -$62.29M | -$27.03M | — | — | — | — | — | — | — | — | — | |
| -$54.27M | -$14.89M | -$62.61M | -$27.43M | -$43.74M | -$41.38M | -$6.02M | -$46.61M | -$46.93M | -$55.67M | -$36.37M | -$31.38M | — | |
| USD/shares | -$0.64 | -$0.19 | -$1.02 | -$0.56 | -$0.89 | -$1.03 | -$0.20 | -$1.59 | — | — | — | — | — |
| USD/shares | -$0.64 | -$0.53 | -$1.02 | -$0.56 | -$0.89 | -$1.03 | -$0.20 | -$1.59 | — | — | — | — | — |
| shares | — | 78.96M | 60.99M | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 373.64K | — |
| shares | — | 79.74M | 60.99M | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 373.64K | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $0 in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 282 similar-size Biotechnology companies (of 515 listed).